According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock.

This stock resale plan was proactively initiated by selling shareholders, aiming to realize partial investment exit through the open market. The company itself is not participating in this stock offering, and therefore will not receive any direct financing proceeds from the stock resale. The document shows that the relevant shareholders have registered the resale qualification for these privately placed stocks, and specific transactions will be carried out opportunistically according to market conditions. As an innovative company in the clinical-stage oncology therapeutic sector, Tempest Therapeutics is currently advancing multiple anti-cancer therapy development projects. This equity change may trigger market attention on its capital structure.